| __timestamp | Incyte Corporation | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3004000 | 22622695 |
| Thursday, January 1, 2015 | 26972000 | 24863028 |
| Friday, January 1, 2016 | 58187000 | 21351001 |
| Sunday, January 1, 2017 | 79479000 | 53837297 |
| Monday, January 1, 2018 | 94123000 | 16080096 |
| Tuesday, January 1, 2019 | 114249000 | 18525736 |
| Wednesday, January 1, 2020 | 131328000 | 2024000 |
| Friday, January 1, 2021 | 150991000 | 2548000 |
| Saturday, January 1, 2022 | 206997000 | 61556000 |
| Sunday, January 1, 2023 | 255000000 | 188157000 |
| Monday, January 1, 2024 | 312068000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Incyte Corporation and Telix Pharmaceuticals Limited from 2014 to 2023. Over this period, Incyte Corporation's cost of revenue surged by over 8,300%, peaking at $255 million in 2023. This reflects a strategic expansion and increased operational scale. In contrast, Telix Pharmaceuticals Limited experienced a more modest increase of approximately 730%, reaching $188 million in the same year. Notably, Telix's costs fluctuated significantly, with a notable dip in 2020, highlighting potential operational challenges or strategic pivots. This comparative insight underscores the dynamic nature of cost management in the pharmaceutical sector, offering a window into each company's growth trajectory and strategic priorities.
Cost of Revenue Comparison: AbbVie Inc. vs Telix Pharmaceuticals Limited
Cost Insights: Breaking Down Sanofi and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Telix Pharmaceuticals Limited
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost of Revenue: Key Insights for Exelixis, Inc. and Telix Pharmaceuticals Limited
Comparing Cost of Revenue Efficiency: Cytokinetics, Incorporated vs Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored